Diversified Trust Co Purchases New Shares in Ascendis Pharma A/S (NASDAQ:ASND)

Diversified Trust Co purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 41,924 shares of the biotechnology company's stock, valued at approximately $6,260,000. Diversified Trust Co owned 0.07% of Ascendis Pharma A/S at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company's stock valued at $616,050,000 after acquiring an additional 44,580 shares during the period. Capital International Investors increased its holdings in shares of Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock valued at $331,261,000 after acquiring an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after acquiring an additional 336,976 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company's stock valued at $233,348,000 after acquiring an additional 93,185 shares during the period.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of analyst reports. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Thursday, September 5th. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Oppenheimer restated an "outperform" rating and set a $190.00 price objective (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Finally, TD Cowen lowered their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating for the company in a research note on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $195.00.

Ascendis Pharma A/S Stock Down 2.5 %

Shares of NASDAQ:ASND traded down $3.53 during midday trading on Monday, reaching $139.14. The company's stock had a trading volume of 222,996 shares, compared to its average volume of 449,247. The firm has a market capitalization of $8.10 billion, a PE ratio of -14.59 and a beta of 0.64. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The stock has a fifty day moving average of $135.44 and a 200 day moving average of $136.30.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. Sell-side analysts anticipate that Ascendis Pharma A/S will post -7.15 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.